RETINOVASCULAR phenomena during migraine are not uncommon, but permanent sequelae are rare. These are usually ascribed to some concomitant organic lesion such as aneurysm, tumor, syphilis ...
The FDA approved Symbravo from Axsome Therapeutics on January 30, 2025, for the acute treatment of migraine in adults. The medication combines two drugs that have been on the market for years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback